Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/3835
Title: Exploring the cytotoxic effects of the extracts and bioactive triterpenoids from Dillenia indica against oral squamous cell carcinoma: A scientific interpretation and validation of indigenous knowledge
Authors: Aswathy, M
Banik, K
Parama, D
Sasikumar, P
Harsha, C
Joseph, A G
Sherin, D R
Thanathu, M K
Kunnumakkara, A B
Radhakrishnan, K V
Keywords: hydrocarbons
cancer
peptides and proteins
apoptosis
assays
cells
Issue Date: 9-Apr-2021
Publisher: American Chemical Society
Citation: Pharmacology & Translational Science; 4(2):834-847
Abstract: Triterpenoids are ubiquitously distributed secondary metabolites, primarily scrutinized as a source of medication and preventive measures for various chronic diseases. The ease of isolation and excellent pharmacological properties of triterpenoids are notable reasons behind the exponential rise of extensive research on the bioactive triterpenoids over the past few decades. Herein, we attempted to explore the anticancer potential of the fruit extract of the ethnomedicinal plant Dillenia indica against oral squamous cell carcinoma (OSCC) and have exclusively attributed the efficacy of the extracts to the presence of two triterpenoids, namely, betulinic acid (BA) and koetjapic acid (KA). Preliminary in vitro screening of both BA and KA unveiled that the entities could impart cytotoxicity and induce apoptosis in OSCC cell lines, which were further well-supported by virtual screening based on ligand binding affinity and molecular dynamic simulations. Additionally, the aforementioned metabolites could significantly modulate the critical players such as Akt/mTOR, NF-κB, and JAK/STAT3 signaling pathways involved in the regulation of important hallmarks of cancer like cell survival, proliferation, invasion, angiogenesis, and metastasis. The present findings provide insight and immense scientific support and integrity to a piece of indigenous knowledge. However, in vivo validation is a requisite for moving to clinical trials and developing it as a commercial drug.
URI: https://pubs.acs.org/doi/10.1021/acsptsci.1c00011
http://hdl.handle.net/123456789/3835
Appears in Collections:2021



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.